Of the two incretin hormones, glucagon-like peptide-1 (GLP-1) has therapeutic potential to reduce body weight and plasma glucose levels
BPC-157 is generally described with more frequent administration, while TB-500 is often described with a higher initial "loading" frequency followed by a lower maintenance frequency
However, the review emphasized that the majority of studies utilized small rodent models, and efficacy in humans remains to be confirmed through adequately powered clinical trials
Outside of direct medical and health insurance costs, improvement of health alleviates drags on economic productivity by reducing death, days absent from work and disabilities (from joint issues)
The four completed Phase 3 trials in the RegeneRx ophthalmic program (ARISE-1 n=317, ARISE-2 n=601, ARISE-3 n=700, and SEER-3 European neurotrophic keratopathy) all missed their pre-specified primary endpoints
Less oversightwhile some compounding pharmacies are excellent, others have less stringent quality control